Capricor Therapeutics (CAPR) reported a Q4 loss late Thursday of $0.62 per diluted share, wider than a loss of $0.16 a year earlier.
Analysts polled by FactSet expected a loss of $0.55.
The company reported no revenue for the quarter ended Dec. 31, compared with $11.1 million a year earlier.
Analysts surveyed by FactSet expected $500,000.
The company said its available cash, cash equivalents and marketable securities of $318.1 million as of the end of 2025 will be enough to cover expenses and capital requirements into 2027.
Shares of Capricor Therapeutics were down 2.2% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments